Dendreon Corp

Dendreon — Merger or Acquisition (June 2003)

14 slides from Dendreon's merger presentation, Jun 10, 2003

  1. Slide 1: Forward-Looking Statement

    Forward-Looking Statement Disclaimer This presentation includes forward-looking statements, including statements about Dendreon’s proposed acquisition of Corvas, post-closing business synergies and product opportunities, and product development and commercialization. Actual results may differ materi

  2. Slide 2: Momentum Continues in 2003

    Momentum Continues in 2003 Significant Scientific Progress • Provenge ® • APC8024 • Alternative reading frames (antigen engineering) Corvas Acquisition • Stock for stock transaction • Valued at $73 M at the time of announcement, an 83% premium to Corvas’ stock price as of 2/24/03 • Value creation fo

  3. Slide 3: Breadth in Oncology

    Breadth in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DVDN CVAS

  4. Slide 4: Advanced Clinical Trial Pipeline

    Advanced Clinical Trial Pipeline Product/Target Phase 1 Phase 2 Phase 3 Provenge ® Androgen Independent Prostate Cancer Completed D9901 D9902 Androgen Dependent Prostate Cancer P-11 (Provenge alone) P-16* (Provenge+Avastin) Mylovenge ™ Multiple Myeloma rNAPc2 Acute Coronary Syndromes APC8024 Breast,

  5. Slide 5: Provenge Induces Significant T-cell Mediated Immune Response

    Provenge Induces Significant T-cell Mediated Immune Response (Week 0 to Week 8) [GRAPHIC]

  6. Slide 6: Gleason Subgroup Change in Immune Response: Confirms MOA

    Gleason £ 7 Subgroup Change in Immune Response: Confirms MOA (Week 0 to Week 8: Provenge Arm) [GRAPHIC]

  7. Slide 7: Provenge P-16 Trial

    Provenge P-16 Trial Combination Therapy with Bevacizumab (Avastin ™ ) Patient Population • Androgen dependent prostate cancer (approx. 4 times size of AIPC market) • Serologic progression after primary therapy Endpoints • Safety • Effect on PSA doubling time • Immune response

  8. Slide 8: P-16 Trial Results to Date

    P-16 Trial Results to Date PSA Doubling Time Pre-Treatment On-Treatment Median 8.2 months 21.4 months PSA Changes Decrease in PSA 3 patients (12%, 33%, 64%)

  9. Slide 9: Provenge Collaboration Discussions

    Provenge Collaboration Discussions • Discussions progressing as planned • Large market, strong data and regulatory plan have driven interest • Competitive process • Will be structured as co-development and co-promotion agreement • Global agreement minus Asia and Oceania

  10. Slide 10: APC8024 Phase Trials

    APC8024 Phase 1 Trials Patient Population • 18 patients enrolled; 16 evaluable • Advanced, metastatic breast cancer patients • Her-2 positive (2+,3+) • Failed multiple courses of chemotherapy including 15/16 who failed Herceptin • Historical median time to progression 3-6 months Endpoints • Safety •

  11. Slide 11: APC8024 Clinical Response

    APC8024 Clinical Response Clinical Benefit 25% (4/16 patients evaluated) Partial Response*: 1 patient, lasting more than 25 weeks Ongoing Stable Disease: 1 patient stable 48+ weeks 2 patients stable for more than one year No significant side effects reported, no evidence of any cardio toxicity * As

  12. Slide 12: Key Messages: American Society of Clinical Oncology 2003 Meeting

    Key Messages: American Society of Clinical Oncology 2003 Meeting • “Immunotherapy may be one of the only ways left to deal with cancer… We’ve gone as far as we can with chemotherapy.” - Dr. Herman Kattlove, American Cancer Society • Cellular therapies will be an important approach in fighting the wa

  13. Slide 13: Preclinical Programs in Oncology

    Preclinical Programs in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DVDN CVAS

  14. Slide 14: Combining Strengths

    Combining Strengths Technology Broad oncology portfolio covering 4 platforms 5 ongoing clinical programs Enhanced intellectual property estate, 87 issued U.S. patents Small molecule, medicinal chemistry expertise Operations Experienced management team Research and development expertise Collaboration

Dendreon — Merger or Acquisition (June 2003) on 6ix